Trial Profile
Post-marketing Surveillance to Assess the Safety and Effectiveness of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the "Standard for Re-examination of New Drugs"
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms Maviret PMS
- Sponsors AbbVie
- 09 Aug 2023 Status changed from active, no longer recruiting to completed.
- 25 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 30 Nov 2022 Planned End Date changed from 30 Sep 2022 to 31 Jul 2023.